Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit [Accessibility Statement] Skip NavigationLOS ANGELES, Feb. 25, 2026 /PRNewswire/ -- [The Law Offices of Frank R. Cruz] announces that investors with losses related to Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: [INO]) have opportunity to lead the securities fraud class action lawsuit.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN INOVIO PHARMACEUTICALS, INC. (INO), CLICK [HER ...

But beneath the selloff, something unusual has emerged.Novo Nordisk is no longer priced like a hypergrowth AI-era healthcare leader. It's priced like a slow-growth legacy pharma stock.NVO Stock Now Trades At A Fraction Of Peer ValuationsAt just 10.6x earnings, NVO stock trades at a dramatic discount to both obesity-drug rival Eli Lilly and Company and broader pharma peers.CompanyP/E Ratio (TTM)Earnings YieldNovo Nordisk10.6x9.42%Eli Lilly45.4x2.20%Vertex Pharmaceuticals31.8x3.14%Pfizer20.0x5.01%Data Source: ...

Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Buy and Hold For the Next 3 Years. On February 19, Eli Lilly and Company (NYSE:LLY) released positive results from the Phase 3 VIVID-2 open-label extension study. The study is testing Omvoh (mirikizumab-mrkz) to treat Crohn’s disease and ulcerative colitis. ​The study found durable remission in Crohn’s, as patients with moderate-to-severe Crohn’s stayed in remission after 3 years of treatment. Moreover, data from VIVID-1 (Crohn’s) and LUCENT-3 ...

Vanda Pharmaceuticals (NASDAQ:VNDA) shares are up during Wednesday’s premarket session following the FDA’s approval of Bysanti, a new oral treatment for bipolar I disorder and schizophrenia, as well as the company’s rare skin disease drug is under FDA review.This approval marks a significant milestone for Vanda, as it positions the company to potentially capture a substantial market share in these therapeutic areas, which is reflected in the stock’s positive movement following the news.Seeks FDA Approval Fo ...

Eli Lilly and Company (NYSE:LLY) is included among the Goldman Sachs Dividend Stocks: Top 14 Stock Picks. Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact On February 24, BofA said Novo Nordisk’s decision to cut GLP-1 list prices may draw attention, but the firm does not expect a meaningful impact on the US market. BofA views the move mainly as an effort to lower copay and coinsurance costs for patients, especially in cases where those costs are tied to the list or WAC pri ...

BofA says that today’s announcement that Novo Nordisk (NVO) plans to slash GLP-1 list prices offers a flashy headline, but in the firm’s view the update is unlikely to have any material impact on the U.S. market. BofA sees today’s move as an attempt to reduce copay/coinsurance costs to patients in settings where that figure is calculated of list/WAC price. More broadly, the firm thinks it’s fair for investors to wonder if/when commercial reimbursement of GLP-1’s could become more commonplace, with BofA cha ...

Market Analysis by covering: Johnson & Johnson. Read 's Market Analysis on Investing.com ...

Key Takeaways CORT posted Q4 EPS of 20 cents, missing estimates. Revenues rose 11% Y/Y to $202.1M in Q4 2025.CORT expects 2026 revenues of $900M-$1B. FDA decision on relacorilant in ovarian cancer is due in July 2026.Corcept received the FDA's CRL for relacorilant in Cushing's syndrome and is engaging in the next steps.Corcept Therapeutics (CORT) reported fourth-quarter 2025 earnings of 20 cents per share, which missed the Zacks Consensus Estimate of 27 cents. The company had reported earnings of 26 cents p ...

Core Insights - Apellis Pharmaceuticals reported a fourth-quarter 2025 loss of 47 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 39 cents, compared to a loss of 29 cents in the same quarter last year [1][7] Financial Performance - Total revenues for the fourth quarter were $199.9 million, exceeding the Zacks Consensus Estimate of $194 million, but down 6% year-over-year from $212.5 million in the previous year [2] - Revenues included product sales from Empaveli and Syfovre, along with licensing and other revenues from a collaboration agreement with Sobi [3] - Syfovre sales were $155.2 million, an 8% decline year-over-year, although it slightly surpassed the Zacks Consensus Estimate of $154.2 million [4] - Empaveli recorded sales of $35.1 million, a 50% increase from the previous year, driven by early launch momentum in C3G and IC-MPGN, and also beat the Zacks Consensus Estimate of $28.5 million [9] Market Position and Product Performance - Syfovre holds approximately 60% market share in geographic atrophy treatment, with total injections growing about 17% year-over-year despite the revenue decline attributed to increased use of free goods [5] - Apellis delivered over 89,000 commercial vials and nearly 13,000 samples of Syfovre to doctors in the reported quarter [5] Cost Management - Research and development expenses decreased by 3% year-over-year to $74.2 million, attributed to lower program-specific external costs and personnel costs [10] - Selling, general, and administrative expenses rose by 21% year-over-year to $147.1 million, driven by higher professional fees and personnel costs [11] Cash Position - As of December 31, 2025, Apellis had cash, cash equivalents, and marketable securities totaling $466.2 million, down from $479.2 million as of September 30, 2025, with expectations that this will fund operations to profitability [12] Annual Performance - For the full year 2025, Apellis reported total revenues of $1.0 billion, a 28% increase year-over-year, surpassing the Zacks Consensus Estimate of $998.3 million, which included a one-time $275 million upfront payment from a royalty repurchase agreement [14] - The company reported earnings per share of 20 cents for 2025, compared to a loss of $1.60 per share in 2024, although it missed the Zacks Consensus Estimate of 24 cents [14] Pipeline Developments - Apellis has initiated two pivotal phase III studies of Empaveli for focal segmental glomerulosclerosis and delayed graft function, both of which are rare kidney diseases with no approved therapies [16] - A mid-stage multi-dose study of siRNA candidate APL-3007 in combination with Syfovre is ongoing, with top-line data expected in 2027 [17]

Core Insights - Johnson & Johnson (JNJ) is a leading player in the oncology segment, particularly in blood cancers and solid tumors, with its drug Darzalex being a foundational treatment [1][11] - JNJ's oncology sales are projected to reach $50 billion by 2030, supported by strong growth in existing products and new drug launches [4][11] Company Performance - JNJ's oncology segment accounts for approximately 27% of total revenues and 42% of its Innovative Medicine segment sales [2] - Oncology sales increased by 20.9% operationally in 2025, driven by Darzalex and Erleada, despite a decline in Imbruvica sales [2][11] - Darzalex generated over $14 billion in sales in 2025, marking a 22% year-over-year increase [1][11] - New cancer drugs Carvykti, Tecvayli, and Talvey contributed $3 billion in sales in 2025 [3][11] Future Outlook - JNJ is optimistic about its oncology pipeline, with expectations of continued momentum and new product launches [4][6] - The company has introduced innovative treatments like Inlexzoh and a subcutaneous formulation of Rybrevant plus Lazcluze, which are expected to enhance sales [5][6] Competitive Landscape - Other major players in the oncology market include Pfizer, AstraZeneca, Merck, and Bristol-Myers, each with significant oncology sales and robust pipelines [7][8][9][10][12] - JNJ's oncology sales growth outpaced competitors, with Pfizer's oncology revenues growing by 8% and AstraZeneca's by 14% in 2025 [8][9] Valuation and Market Performance - JNJ's stock has outperformed the industry, rising 51% over the past year compared to a 12.7% increase in the industry [13] - The company's shares are currently trading at a price/earnings ratio of 21.11, higher than the industry average of 18.69 [14]